![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhBg-vcpMPugdI1GudYyOdcy142HmuOJu3ELpCFn5Fn7Gs3WWyTXJbeUD9hJt0YLvnThqr3ryGybB7QD5JoOsk9tB0ZYjzOcU4cqJtNZgVVLq3yZ08kzfY7GTxyt9GG2DjNrC64JQwyw8eC/s320/CAPR2022012820220214-780267.png)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
http://www.priceseries.com/trade/CAPR-Capricor-Therapeutics-Inc-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2022012820220214.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments